X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES NOVARTIS VENUS REMEDIES/
NOVARTIS
 
P/E (TTM) x -4.4 328.0 - View Chart
P/BV x 0.2 36.4 0.5% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 VENUS REMEDIES   NOVARTIS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
NOVARTIS
Mar-18
VENUS REMEDIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs126758 16.6%   
Low Rs61579 10.6%   
Sales per share (Unadj.) Rs301.8228.4 132.1%  
Earnings per share (Unadj.) Rs-24.931.7 -78.4%  
Cash flow per share (Unadj.) Rs2.532.8 7.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs293.3297.1 98.7%  
Shares outstanding (eoy) m12.3424.69 50.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.6%   
Avg P/E ratio x-3.821.1 -17.8%  
P/CF ratio (eoy) x36.720.4 180.1%  
Price / Book Value ratio x0.32.2 14.2%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m1,15416,505 7.0%   
No. of employees `0000.90.7 138.5%   
Total wages/salary Rs m3931,445 27.2%   
Avg. sales/employee Rs Th4,026.18,441.3 47.7%   
Avg. wages/employee Rs Th425.02,163.6 19.6%   
Avg. net profit/employee Rs Th-331.81,173.1 -28.3%   
INCOME DATA
Net Sales Rs m3,7245,639 66.0%  
Other income Rs m231,718 1.3%   
Total revenues Rs m3,7477,357 50.9%   
Gross profit Rs m395-63 -631.7%  
Depreciation Rs m33825 1,337.2%   
Interest Rs m35455 640.7%   
Profit before tax Rs m-2751,575 -17.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32792 4.0%   
Profit after tax Rs m-307784 -39.2%  
Gross profit margin %10.6-1.1 -956.5%  
Effective tax rate %-11.550.3 -22.8%   
Net profit margin %-8.213.9 -59.3%  
BALANCE SHEET DATA
Current assets Rs m2,6389,522 27.7%   
Current liabilities Rs m2,3053,296 69.9%   
Net working cap to sales %8.9110.4 8.1%  
Current ratio x1.12.9 39.6%  
Inventory Days Days13537 369.9%  
Debtors Days Days4628 163.0%  
Net fixed assets Rs m4,87146 10,588.6%   
Share capital Rs m123123 100.0%   
"Free" reserves Rs m3,4967,213 48.5%   
Net worth Rs m3,6197,336 49.3%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50911,105 67.6%  
Interest coverage x0.229.5 0.8%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.5 97.7%   
Return on assets %0.67.6 8.4%  
Return on equity %-8.510.7 -79.4%  
Return on capital %1.622.2 7.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m061 0.0%   
Fx outflow Rs m5173,630 14.2%   
Net fx Rs m-517-3,570 14.5%   
CASH FLOW
From Operations Rs m5141,610 32.0%  
From Investments Rs m-123687 -17.9%  
From Financial Activity Rs m-387-2,677 14.5%  
Net Cashflow Rs m4-380 -1.1%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 2.0 9.0%  
FIIs % 0.6 1.6 36.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 21.5 308.8%  
Shareholders   20,121 41,647 48.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS